CY1114166T1 - Ενωση ακυλοθειουριας ή αλας αυτης, και χρηση της ενωσης ή του αλατος - Google Patents

Ενωση ακυλοθειουριας ή αλας αυτης, και χρηση της ενωσης ή του αλατος

Info

Publication number
CY1114166T1
CY1114166T1 CY20131100625T CY131100625T CY1114166T1 CY 1114166 T1 CY1114166 T1 CY 1114166T1 CY 20131100625 T CY20131100625 T CY 20131100625T CY 131100625 T CY131100625 T CY 131100625T CY 1114166 T1 CY1114166 T1 CY 1114166T1
Authority
CY
Cyprus
Prior art keywords
union
salt
unclassified
met
mitigates
Prior art date
Application number
CY20131100625T
Other languages
English (en)
Inventor
Yoshimitsu Suda
Kosuke Egami
Hidenori Fujita
Original Assignee
Taiho Pharmaceutical Co., Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co., Ltd filed Critical Taiho Pharmaceutical Co., Ltd
Publication of CY1114166T1 publication Critical patent/CY1114166T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)

Abstract

Για την παροχή ενός αντικαρκινικού παράγοντα ο οποίος εμφανίζει εξαιρετικό ανασταλτικό του c-Met αποτέλεσμα και μετριάζει τις παρενέργειες λόγω επιλεκτικής επενέργειας επί κυττάρων όγκου στα οποία εκφράζεται ειδικώς το c-Met. H εφεύρεση παρέχει μια ένωση ακυλοθειουρίας που παριστάνεται με τον τύπο (Ι):
CY20131100625T 2008-04-10 2013-07-23 Ενωση ακυλοθειουριας ή αλας αυτης, και χρηση της ενωσης ή του αλατος CY1114166T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2008102832 2008-04-10
EP09730440.6A EP2287155B1 (en) 2008-04-10 2009-04-09 Acylthiourea compound or salt thereof, and use thereof

Publications (1)

Publication Number Publication Date
CY1114166T1 true CY1114166T1 (el) 2016-08-31

Family

ID=41161733

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20131100625T CY1114166T1 (el) 2008-04-10 2013-07-23 Ενωση ακυλοθειουριας ή αλας αυτης, και χρηση της ενωσης ή του αλατος

Country Status (20)

Country Link
US (1) US8304427B2 (el)
EP (1) EP2287155B1 (el)
JP (1) JP4667537B2 (el)
KR (1) KR101414931B1 (el)
CN (1) CN101998951B (el)
AU (1) AU2009234978B2 (el)
BR (1) BRPI0911679B8 (el)
CA (1) CA2720552C (el)
CY (1) CY1114166T1 (el)
DK (1) DK2287155T3 (el)
ES (1) ES2423851T3 (el)
HK (1) HK1151288A1 (el)
HR (1) HRP20130984T1 (el)
MX (1) MX2010011097A (el)
PL (1) PL2287155T3 (el)
PT (1) PT2287155E (el)
RU (1) RU2503664C2 (el)
SI (1) SI2287155T1 (el)
TW (1) TWI438193B (el)
WO (1) WO2009125597A1 (el)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9314253B2 (en) 2008-07-01 2016-04-19 Amendia, Inc. Tissue modification devices and methods
AU2009303602B2 (en) 2008-10-14 2012-06-14 Sunshine Lake Pharma Co., Ltd. Compounds and methods of use
SG173867A1 (en) 2009-03-21 2011-10-28 Ning Xi Amino ester derivatives, salts thereof and methods of use
WO2012008563A1 (ja) 2010-07-16 2012-01-19 協和発酵キリン株式会社 含窒素芳香族複素環誘導体
WO2012121273A1 (ja) * 2011-03-07 2012-09-13 味の素株式会社 塩味増強剤
TWI594986B (zh) 2011-12-28 2017-08-11 Taiho Pharmaceutical Co Ltd Antineoplastic agent effect enhancer
WO2013111798A1 (ja) 2012-01-27 2013-08-01 国立大学法人 富山大学 セリンラセマーゼ阻害剤
US9149471B2 (en) 2013-09-30 2015-10-06 National University Corporation Tokyo University Of Agriculture And Technology Therapeutic agent for osteoporosis
EP3293177A4 (en) * 2015-04-07 2018-12-12 Guangdong Zhongsheng Pharmaceutical Co., Ltd Tyrosine kinase inhibitor and pharmaceutical composition comprising same
ES2863586T3 (es) 2015-04-30 2021-10-11 Taiho Pharmaceutical Co Ltd Sal del ácido mesílico de un compuesto de aciltiourea, cristal de la misma y proceso para su producción
EP3973962A1 (en) * 2015-06-25 2022-03-30 Taiho Pharmaceutical Co., Ltd. Therapeutic agent for fibrosis
CN105601566A (zh) * 2016-02-02 2016-05-25 张敏 一种护理烧伤后感染的药物组合物
WO2018028591A1 (zh) * 2016-08-09 2018-02-15 殷建明 一种喹啉衍生物及其用途
MY194278A (en) 2017-02-15 2022-11-25 Taiho Pharmaceutical Co Ltd Pharmaceutical composition
KR102584306B1 (ko) * 2017-09-08 2023-10-04 다이호야쿠힌고교 가부시키가이샤 항종양제 및 항종양 효과 증강제
KR20210060465A (ko) 2018-09-18 2021-05-26 다이호야쿠힌고교 가부시키가이샤 아실티오우레아 화합물과 아비라테론의 병용 요법
TW202140426A (zh) 2020-02-14 2021-11-01 日商大鵬藥品工業股份有限公司 醯基硫脲化合物的製造方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL102548A (en) * 1991-08-02 1998-08-16 Medivir Ab Use of painting derivatives in the preparation of drugs for VIH inhibition and treatment of SDIA and new compounds
US7135466B2 (en) * 1999-12-24 2006-11-14 Kirin Beer Kabushiki Kaisha Quinoline and quinazoline derivatives and drugs containing the same
DE60137273D1 (de) 2000-10-20 2009-02-12 Eisai R&D Man Co Ltd Verfahren zur Herstellung von 4-Phenoxy chinolin Derivaten
EP2088141A3 (en) * 2001-06-22 2009-11-18 Kirin Pharma Kabushiki Kaisha Quinoline derivatives and quinazoline derivatives capable of inhibiting autophosphorylation of hepatocyte growth factor receptors, and pharmaceutical composition comprising the same
US6858637B2 (en) 2002-03-28 2005-02-22 Neurogen Corporation Substituted biaryl amides as C5a receptor modulators
ES2651730T3 (es) 2003-09-26 2018-01-29 Exelixis, Inc. Moduladores c-Met y métodos de uso
TW200538120A (en) 2004-02-20 2005-12-01 Kirin Brewery Compound having TGF-beta inhibitory activity and pharmaceutical composition containing same
US20070270421A1 (en) 2004-02-27 2007-11-22 Tomohiro Matsushima Novel pyridine Derivative and Pyrimidine Derivative (1)
WO2005121125A1 (en) 2004-06-09 2005-12-22 Pfizer Inc. Ether-linked heteroaryl compounds
AU2006229343A1 (en) * 2005-03-28 2006-10-05 Kirin Pharma Kabushiki Kaisha Thienopyridine derivative, or quinoline derivative, or quinazoline derivative, having c-Met autophosphorylation inhibiting potency
CA2603748A1 (en) * 2005-04-06 2006-10-12 Exelixis, Inc. C-met modulators and methods of use

Also Published As

Publication number Publication date
JP4667537B2 (ja) 2011-04-13
AU2009234978A1 (en) 2009-10-15
CN101998951B (zh) 2013-07-17
HRP20130984T1 (hr) 2013-11-22
PL2287155T3 (pl) 2013-12-31
TWI438193B (zh) 2014-05-21
WO2009125597A1 (ja) 2009-10-15
RU2010145526A (ru) 2012-05-20
BRPI0911679A2 (pt) 2015-10-13
EP2287155A4 (en) 2012-05-09
KR101414931B1 (ko) 2014-07-04
CA2720552A1 (en) 2009-10-15
JPWO2009125597A1 (ja) 2011-08-04
TW201000451A (en) 2010-01-01
ES2423851T3 (es) 2013-09-24
KR20100132023A (ko) 2010-12-16
BRPI0911679B1 (pt) 2020-09-29
MX2010011097A (es) 2010-11-01
SI2287155T1 (sl) 2013-10-30
DK2287155T3 (da) 2013-07-29
PT2287155E (pt) 2013-07-26
AU2009234978B2 (en) 2014-03-06
BRPI0911679B8 (pt) 2021-05-25
EP2287155A1 (en) 2011-02-23
HK1151288A1 (en) 2012-01-27
CN101998951A (zh) 2011-03-30
EP2287155B1 (en) 2013-07-17
RU2503664C2 (ru) 2014-01-10
US8304427B2 (en) 2012-11-06
CA2720552C (en) 2016-06-14
US20110034439A1 (en) 2011-02-10

Similar Documents

Publication Publication Date Title
CY1114166T1 (el) Ενωση ακυλοθειουριας ή αλας αυτης, και χρηση της ενωσης ή του αλατος
CY1122186T1 (el) Μεθοδοι θεραπειας καρκινου
CY1121129T1 (el) Αναστολεις toy fgfr4 πυριμιδινης
CY1121468T1 (el) Συνδυασμος παραγωγων πυρρολο[2,3-d]πυριμιδινης με εναν ή περισσοτερους επιπροσθετους παραγοντες ως αναστολεις των σχετικων me janus (ιανος) kinασων (jak)
CY1120635T1 (el) Βενζαμιδια αμινοετεροαρυλιου ως αναστολεις κινασης
CY1117986T1 (el) Ενωσεις αρυλ- ή ετεροαρυλ-υποκατεστημενου βενζολιου
EA201591317A1 (ru) Соединения тубулизина, способы их получения и применение
EA201690098A1 (ru) Конденсированные трициклические соединения мочевины в качестве ингибиторов киназы raf и/или димера киназы raf
EA201291194A1 (ru) Индолы
CR20140468A (es) Inhibidores de diacilglicerol aciltransferasa 2
EA201692219A1 (ru) Способы получения противовирусных соединений
BR112016006209A2 (pt) composição de polímero termoplástico
EA201270257A1 (ru) Производные n1-сульфонил-5-фторпиримидинона
EA201792682A1 (ru) Пирролбензодиазепины и их конъюгаты
ECSP15032846A (es) Derivados de n-(sustituido)-5-fluoro-4-imino-3-metil-2-oxo-3,4-dihidropirimidin-1(2h)-carboximida
UA108101C2 (xx) Похідні n3-заміщених n1-сульфоніл-5-фторпіримідинонів
CR20150470A (es) Derivados de triazolona de piridinilo y piridinilo fusionado
BR112015028152A2 (pt) inibidores de acc e usos dos mesmos
EA201401081A1 (ru) Циклические амиды в качестве ингибиторов метар-2
EA201390081A1 (ru) Дейтерированный n-этил-n-фенил-1,2-дигидро-4-гидрокси-5-хлор-1-метил-2-оксохинолин-3-карбоксамид, его соли и их применение
EA201270254A1 (ru) Производные 5-фторпиримидинона
EA201501111A1 (ru) Замещенные n-(тетразол-5-ил)- и n-(триазол-5-ил)арилкарбоксамидные соединения и их применение в качестве гербицидов
MA38982A1 (fr) Nouvel octahydro-cyclobuta [1,2-c; 3,4-c'] dipyrrol-2-yl
EA201401189A1 (ru) Замещенные n-(тетразол-5-ил)- и n-(триазол-5-ил)арилкарбоксамидные соединения и их применение в качестве гербицидов
EA201170288A1 (ru) Оксабициклогептаны и оксабициклогептены, их получение и применение